CoChat
Sign Up
Cited by 84Luminescence Properties of Advanced MaterialsAlzheimer's disease research and treatmentsMolecular Sensors and Ion Detection

Sensitive imaging and effective capture of Cu2+: Towards highly efficient theranostics of Alzheimer's disease

Cui, Zhaowen, Bu, Wenbo, Fan, Wenpei, Zhang, Jiawen, Ni, Dalong, Liu, Yanyan, Wang, Jing, Liu, Jianan +2 more·2016·Biomaterials
DOI 10.1016/j.biomaterials.2016.06.056
Open this paper in CoChat — free account

Abstract

As a distinct feature of Alzheimer's disease (AD), the presence of excess metal ions in the brain is most probably one of the main causative factors for the aggregation of β-Amyloid (Aβ) proteins. The design of nanoprobes for detection and control of ion concentrations will be of great importance in predicting the progression of AD and simultaneously providing effective treatments. Herein, we report the design and synthesis of a novel yet smart nanoprobe that can sensitively detect the Cu(2+) concentration and concurrently capture Cu(2+) both in vitro and in vivo. The designed nanoprobe (UCHQ) combines two main components: upconversion nanoparticles (UCNPs) used for the detection and upconversion luminescence (UCL) imaging of Cu(2+) upon 980 nm exposure and the chelator 8-hydroxyquinoline-2-carboxylic acid (HQC) used for chelating Cu(2+) and AD therapy. The results show that the emission intensity of UCHQ is highly dependent on the Cu(2+) concentrations due to the luminescence resonance energy transfer (LRET) from UCNPs to HQC-bonded Cu(2+). Fascinatingly, the as-constructed UCHQs could be used for UCL imaging of Aβ both in cells and AD mice. Most importantly, UCHQs could not only inhibit the Aβ aggregation-induced apoptosis via capturing overmuch Cu(2+) but also accelerate the nontoxic structural transformation of Aβ.

Integrity signals

Registry

Crossref · 10.1016/j.biomaterials.2016.06.056

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cui et al. constructed UCHQs-upconversion luminescence Nps coated with DSPE-PEG and functionalized with HQC; the upconversion core provides luminescence imaging, while HQC chelates Cu2+ ions, reducing metal-induced oxidative stress and inhibiting Cu2+-catalyzed Aβ aggregation.

    “Cui et al. [69] constructed UCHQs—upconversion luminescence Nps (NaYF4:Yb/Er/Tm) coated with DSPE-PEG and functionalized with 8-hydroxyquinoline-2-carboxylic acid (HQC). Here, the upconversion core provides luminescence imaging, while HQC chelates Cu2+ ions, simultaneously reducing metal-induced oxidative stress and inhibiting Cu2+-catalyzed Aβ aggregation.”

    From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [69]

  • Leading examples exhibit true component synergy.

    “Leading examples exhibit true component synergy [64,69,83].”

    From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [69]

  • A nanoprobe containing chelator-8-hydroxyquinoline-2-carboxylic acid can detect copper concentration upon exposure to 980 nm.

    “Based on this observation, scientists have developed a nanoprobe containing a chelator-8-hydroxyquinoline-2-carboxylic acid, which can detect copper concentration upon exposure to 980 nm.”

    From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [109]

  • Chelators capture excess copper ions in the brain and inhibit amyloid plaque induced apoptosis and cause structural transformation of Aβ.

    “Chelators capture excess copper ions in the brain and inhibit amyloid plaque induced apoptosis and also causes the structural transformation of Aβ [109].”

    From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [109]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Cui, Z., Bu, W., Fan, W., Zhang, J., Ni, D., Liu, Y., Wang, J., Liu, J., Yao, Z., & Shi, J.
Affiliations
  • Chinese Academy of Sciences (CN)
  • Fudan University (CN)
Corresponding author
  • Bu, Wenbo
  • Shi, Jianlin
ORCID
Venue
Biomaterials
Publisher
Elsevier BV
Published
2016-10
Volume
104
Pages
158-167
ISSN
0142-9612 (ISSN-L)
DOI
10.1016/j.biomaterials.2016.06.056
OpenAlex
W2463454730
Cited by
83
References
49
Citations by year
2025: 10 · 2024: 8 · 2023: 8 · 2022: 8 · 2021: 8 · 2020: 8 · 2019: 14 · 2018: 15 · 2017: 4
FWCI
4.89
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Biomaterials (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (51372260, 51132009, 51402338)
  • Shanghai Excellent Academic Leaders Program (16XD1404000)
  • Shanghai Yangfan Program (14YF1406400)
  • Youth Innovation Promotion Association CAS (2015201)
Topics
  • Physical Sciences › Materials Science › Materials Chemistry › Luminescence Properties of Advanced Materials
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Physical Sciences › Chemistry › Spectroscopy › Molecular Sensors and Ion Detection
Keywords
Alzheimer's disease, copper(II) determination, upconversion nanoparticles, luminescence resonance energy transfer, copper chelation, amyloid-beta aggregation, theranostics, apoptosis inhibition
MeSH terms
Theranostic Nanomedicine, Alzheimer Disease, Animals, Chelating Agents, Copper, Female, Humans, Luminescent Measurements, Mice, Inbred C57BL, Mice, Transgenic, Treatment Outcome, Mice, Nanoparticles, Molecular Imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review